Jan. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B ...
Jan. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B ...
Zacks.com on MSN17d
Denali's ALS Study Fails to Meet Primary and Secondary EndpointsDNLI's DNL343 fails to achieve the primary and secondary endpoints, as observed from an analysis of Regimen G of the phase II ...
BTIG analyst Thomas Shrader lowered the firm’s price target on Denali Therapeutics (DNLI) to $32 from $35 and keeps a Buy rating on the shares ...
A study of human brain organoids suggested a complex relationship between herpes simplex virus 1 infection and tau, suggesting that tau phosphorylation may act as an innate immune response in ...
Zacks.com on MSN3d
Denali Gains 26.6% in a Year: How Should You Play the Stock?Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained ...
The central nervous system candidate is eIF2B activator ABBV-CLS-7262, in a multiple dose study to assess its safety and pharmacokinetics in patients with amyotrophic lateral sclerosis ...
For the primary analysis, a total of 186 participants who received DNL343 treatment were compared to 139 participants who ...
DNL343 is an investigational candidate operated by targeting eukaryotic initiation factor 2B (eIF2B), a key regulator of the integrated stress response. This is considered a new small molecule ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback